RecruitingNCT06657131

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Diagnostic Performance and Clinical Impact of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer: a Real-World Evidence from a Monocentric, Prospective Observational Phase-4-Trial

Sponsor

Heinrich-Heine University, Duesseldorf

Enrollment

250 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Biochemical Recurrence of Malignant Neoplasm of Prostate Prostate Cancer After a Radical Treatment Biochemical Persistence of Prostate Cancer

Summary

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating how well a specialized PET scan using a radioactive tracer called [18F]PSMA-1007 can detect where prostate cancer has returned after treatment, in men whose PSA level is rising (called biochemical recurrence) but standard imaging may not yet show where the cancer is. **You may be eligible if...** - You have a history of treated prostate cancer - Your PSA level is rising after treatment (biochemical recurrence) - Your doctor has ordered a [18F]PSMA-1007 PET scan as part of your regular clinical care **You may NOT be eligible if...** - You did not have a [18F]PSMA-1007 PET scan performed - There were technical problems with your scan that make it unusable Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.